NuVasive Announces Sponsorship Of EPOSNA 2017 And Launches New Monthly Pediatric Spinal Deformity Podcast

NuVasive Announces Sponsorship Of EPOSNA 2017 And Launches New Monthly Pediatric Spinal Deformity Podcast

Share this story with your network

SAN DIEGO, May 2, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the Company is a leading sponsor of EPOSNA 2017, the combined meeting of the EPOS (European Paediatric Orthopaedic Society) and POSNA (Pediatric Orthopaedic Society of North America) annual meetings, held this week in Barcelona, Spain. NuVasive also announced the launch of a monthly podcast, MAGEC Matters, featuring interviews with the leading surgeons in pediatric deformity and sharing clinical insights on the treatment of early-onset scoliosis.

“At NuVasive, we are not only passionate about the world-class innovation we are bringing to market to help improve pediatric spinal deformity, but we’re also passionate about the education and research that is necessary to provide surgeons with the information they need to advance the care options available to pediatric patients,” said Jason Hannon, NuVasive’s president and chief operating officer. “We’ve made tremendous investments in building a comprehensive pediatric deformity portfolio, with our MAGEC® system, RELINE®posterior fixation platform and PRECICE® limb lengthening system. By supporting events such as EPOSNA, we are able to connect surgeons from around the world and help improve the lives of children.”

EPOSNA is the world’s largest pediatric orthopaedic scientific meeting with over 1,300 abstracts submitted. The Company’s sponsorship of the event includes exhibit floor presence featuring pediatric spine and orthopedic solutions and the following workshops:

  • “MAGEC Masters Roundtable: Key Principles for Challenging Applications”; Wednesday, May 3, 2017 from 12:45 – 13:35 p.m. (CEST); Featuring Michael Vitale, M.D., Peter Sturm, M.D., Burt Yaszay, M.D. and Jeff Sawyer, M.D.
  • “So You’re Not Sure You Can Do Limb Lengthening”; Thursday, May 4, 2017 from 12:45 – 13:35 p.m. (CEST); Featuring Christof Radler, M.D. and Frank Schiedel, M.D.

As a key education initiative for the pediatric spinal deformity community, NuVasive also announced the launch of a monthly podcast series, MAGEC Matters, featuring interviews with leading surgeons in pediatric deformity discussing tips for the treatment of early-onset scoliosis, which is now available on iTunes, SoundCloud and other leading podcast platforms.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

 

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

Leave a Comment

Your email address will not be published. Required fields are marked *

*